详情页 - 河北大学附属医院知识库

资源类型：

文章类型：

作者：

Ma, Fei[1] * ; Qiu, Fuming[2] ; Tong, Zhongsheng[3] ; Shi, Yehui[4] ; Yu, Guohua[5] ; Wu, Xinhong[6] ; Wang, Hong[7] ; Wang, Jiani[8] ; Yang, Hua[9]

; Liu, Anwen[10] ; Zhang, Yan[11] ; Zheng, Hongmei[12] ; Lan, Qiongyu[13] ; Zhang, Yongqiang[14] ; Cheng, Ying[15] ; Zhou, Qing[16] ; Xing, Xiaoyan[17] ; Chen, Xiaomei[16] ;

机构： [1]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China [2]Department of Medical Oncology, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China [3]Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China [4]Tianjin Medical University Cancer Institute and Hospital, Tianjin, China [5]Weifang People's Hospital & The First Affiliated Hospital of Weifang Medical University, Weifang, China [6]Department of Breast Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology/ Hubei Provincial Clinical Research Center for Breast Cancer/ Wuhan Clinical Research Center for Breast Cancer, Wuhan, China [7]The Nanchang Third Hospital, Nanchang, China [8]Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China [9]Affiliated Hospital of Hebei University, Hebei, China [10]The Second Affiliated Hospital of Nanchang University, Nanchang, China [11]The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China [12]Department of Breast Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology/ Hubei Provincial Clinical Research Center for Breast Cancer, and Wuhan Clinical Research Center for Breast Cancer, Wuhan, China [13]Department of Oncology, the Second Affiliated Hospital of Nanchang University, Nanchang, China [14]Beijing Hospital, Beijing, China [15]Jilin Cancer Hospital, Changchun, China [16]Shanghai Escugen Biotechnology Co., Ltd., Shanghai, China [17]Shanghai Escugen Biotechnology Co., Ltd., Beijing, China

出处：

ISSN：

基金：

语种：

WOS：

中科院(CAS)分区：

出版当年[2025]版：

无

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2024]版：

无

最新[2023]版：

Q1 ONCOLOGY

第一作者：

第一作者机构： [1]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), for the treatment of first-line metastatic triple negative breast cancer (mTNBC)

文献详情